688236 Beijing Chunlizhengda Medical Instruments
- 22.22
- +0.06+0.27%
Beijing Chunlizhengda Medical Instruments News
Chunli Medical's net profit of 55,1996 million yuan in the first quarter decreased by 1.18% year-on-year
Chunli Medical (01858) released its report for the first quarter of 2024, with operating income of 222 million yuan (RMB, same below), down 9.95% year on year; net profit attributable to shareholders of listed companies was 55,1996 million yuan, down 1.18% year on year; basic earnings per share were 0.14 yuan.
春立醫療：2024年第一季度報告
春立醫療：2023 年報
Chunli Medical (688236.SH) announced first-quarter results, net profit of 55.2 million yuan, a year-on-year decrease of 1.18%
Chunli Medical (688236.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 2.2 during the reporting period...
Chunli Medical (01858.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Gelonghui, April 17, 丨 Chunli Healthcare (01858.HK) issued an announcement. The board of directors will hold a board meeting on April 29, 2024 (Monday) to approve (among others) the announcement of the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and consider paying an interim dividend (if any).
From the pain of collection to the decline in net profit distribution, going overseas or becoming the only way out for orthopedic consumables?
As the fourth batch of high-value consumables collected last year directly targeted artificial lenses and high-value orthopedic sports medicine consumables, almost all high-value consumables in the orthopedic field have already been collected. Even if this collection is “mild” compared to the previous three rounds of overall price cuts, it will inevitably have a negative impact on the performance of leading domestic companies in the short term, and there is a certain relationship with the imbalance in the companies' “price for volume” game. Judging from the 2023 financial reports disclosed by many industry companies, the traditional logic of “price for volume” collection has not been fully demonstrated. It is not that the more companies that win the bid, the better their performance growth. On the contrary, the increase in sales brought about by harvesting does not seem to offset the product
CHUNLI MEDICAL To Go Ex-Dividend On July 2nd, 2024 With 0.39918 HKD Dividend Per Share
March 31st - $CHUNLI MEDICAL(01858.HK)$ is trading ex-dividend on July 2nd, 2024. Shareholders of record on July 3rd, 2024 will receive 0.39918 HKD dividend per share on July 31st, 2024. The ex-di
Chunli Medical (01858): Wang Jianliang resigns as Deputy General Manager
Zhitong Finance App News, Chunli Medical (01858) issued an announcement. The board of directors recently received a written resignation application from Mr. Wang Jianliang, the company's deputy general manager, to resign as the company's deputy general manager due to personal reasons. After his resignation, Mr. Wang Jianliang will continue to work for the company.
Chunli Medical (01858) will pay a final dividend of 3.62 yuan for every 10 shares on July 31
According to the Zhitong Finance App, Chunli Healthcare (01858) announced that the company will pay a final dividend of RMB 3.62 per 10 shares on July 31, 2024.
Chunli Medical (01858) announced 2023 annual results, net profit of 278 million yuan, a year-on-year decrease of 9.72%, and final interest of 3.62 yuan per 10 shares
Chunli Medical (01858) announced its annual results for the year ended December 31, 2023. The group will take...
CHUNLI MEDICAL: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Chunli Healthcare (01858.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Gelonghui, March 18, 丨 Chunli Healthcare (01858.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to approve (among other things) the announcement of the annual results of the Company and its subsidiaries for the financial year ended 31 December 2023 and consider payment of a final dividend (if any).
CHUNLI MEDICAL: NOTICE OF BOARD MEETING
Chunli Medical (01858) subscribed to structured deposit products with a total amount of 160 million yuan
Chunli Medical (01858) issued an announcement. On March 12, 2024, the company established Bank of Beijing (Fangzhuang Branch)...
Changes in Hong Kong stocks | Chunli Healthcare (01858) fell by more than 4% due to orthopedic collection, terminal sales prices fell, and the company did not increase profit last year
Chunli Healthcare (01858) fell by more than 4%. As of press release, it was down 4.37% to HK$9.64, with a turnover of HK$2,522,100.
Chunli Medical (688236.SH) performance report: 2023 net profit of 278 million yuan fell 9.72% year on year
Gelonghui, Feb. 28, 丨 Chunli Medical (688236.SH) announced the 2023 annual performance report. In 2023, the company achieved total operating revenue of 1,209 million yuan, an increase of 0.58% over the same period of the previous year; realized net profit attributable to owners of the parent company of 278 million yuan, a decrease of 9.72% over the same period of the previous year; realized net profit attributable to owners of the parent company after deducting non-recurring gains and losses of 254 million yuan, down 7.32% from the same period last year; achieved basic earnings per share of 0.72 yuan, down 10.00% from the same period last year.
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 5%, leading medical device stock institutions optimistic about the future prospects of overseas expansion of domestic medical devices
The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
Chunli Medical (01858) subscribed to Bank of Beijing's 580 million yuan structured deposit products
Zhitong Finance App News, Chunli Healthcare (01858) announced that on January 18, 2024, the company entered into a structured deposit product agreement with the Bank of Beijing (Daxing Branch), agreeing to use its temporary idle funds raised from the A-share public offering to subscribe to structured deposit products of Bank of Beijing (Daxing Branch), with a total amount of RMB 335 million; and Bank of Beijing (Fangzhuang Branch) structured deposit product agreement 7. It agreed to use its temporary idle fund-raising capital and internal resources from the A-share public offering to subscribe to structured deposit products of Bank of Beijing (Fangzhuang Branch). Total amount RMB245 million
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
Analysis
Price Target
No Data
